Real-World Study on the Effectiveness and Breast Safety Analysis of Hormone Replacement Therapy During Menopause - Report - MDSpire

Real-World Study on the Effectiveness and Breast Safety Analysis of Hormone Replacement Therapy During Menopause

  • By

  • Wang, Yingxia

  • Liu, Yaqin

  • Zeng, Jing

  • Wang, Mengyi

  • Li, Yuhuan

  • Wu, Yinglan

  • Gao, Jie

  • Chen, Xia

  • May 21, 2026

  • 0 min

Share

Clinical Report: Evaluation of Hormone Replacement Therapy's Efficacy and Breast Safety

Overview

This study assessed the effects of 24-month menopausal hormone therapy (MHT) on bone mineral density (BMD), menopausal symptoms, and breast safety in postmenopausal women. Results indicated significant improvements in BMD and menopausal symptoms, while breast safety remained favorable.

Background

Menopausal hormone therapy (MHT) is a critical intervention for managing symptoms associated with menopause and for maintaining bone health in postmenopausal women. Understanding the efficacy and safety of MHT is essential, particularly in light of previous concerns regarding breast cancer risk associated with hormone therapies. This study contributes to the growing body of evidence regarding the benefits and safety profile of MHT.

Data Highlights

OutcomeBaseline24 MonthsP-value
Osteoporosis Prevalence18.0%14.0%< 0.001
Low Bone Mass Prevalence27.4%21.4%< 0.001
Kuppermann Score40.17 ± 6.0411.38 ± 4.90< 0.001

Key Findings

  • The prevalence of osteoporosis decreased from 18.0% to 14.0% over 24 months (P < 0.001).
  • The prevalence of low bone mass decreased from 27.4% to 21.4% (P < 0.001).
  • BMD showed significant improvement at all post-treatment time points (all P < 0.001).
  • The mean Kuppermann score improved significantly from 40.17 ± 6.04 to 11.38 ± 4.90 (P < 0.001).
  • No significant changes were observed in breast density, volume, or prevalence of calcifications or masses (all P > 0.05).

Clinical Implications

The findings suggest that a 24-month regimen of MHT can effectively improve bone health and alleviate menopausal symptoms without adversely affecting breast safety. Clinicians should consider these outcomes when discussing MHT with postmenopausal patients.

Conclusion

The study supports the use of MHT for improving bone mineral density and managing menopausal symptoms while maintaining a favorable breast safety profile.

Related Resources & Content

  1. The ASCO Post, 2020 -- Postmenopausal Estrogen and Risk of Breast Cancer: What Is the Real Story?
  2. conexiant, Rethinking Menopause Hormone Therapy
  3. The ASCO Post, 2015 -- Differing Patterns of Breast Cancer Risk After Hormone Therapy With Estrogen Plus Progestin or Estrogen Alone
  4. European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause | European Journal of Endocrinology | Oxford Academic
  5. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials | Breast Cancer | JAMA | JAMA Network
  6. Clinical Research in Cardiology — Impact of Estrogen and Progestin Therapy on Hemodynamics and Metabolism in Hypertensive Postmenopausal Women Undergoing ACE-Inhibitor or Diuretic Treatment
  7. European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause | European Journal of Endocrinology | Oxford Academic
  8. https://www.imsociety.org/wp-content/uploads/2026/03/IMS-Recommendations-Full-Document.pdf
  9. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials | Breast Cancer | JAMA | JAMA Network

Original Source(s)

Real-World Study on the Effectiveness and Breast Safety Analysis of Hormone Replacement Therapy During Menopause

  • by Wang, Yingxia , Liu, Yaqin , Zeng, Jing , Wang, Mengyi , Li, Yuhuan , Wu, Yinglan , Gao, Jie , Chen, Xia

  • May 21, 2026

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Medical Oddities: When Body Fat Gets to Your Head

From colds to cognition, these studies show how everyday science—viruses, fat, bones, herbs, even AI— meets fine the print.

What Should Doctors Know About FDA’s Black Box Change for Hormone Replacement Therapy Drugs?

A Keck Medicine of USC breast surgeon discusses the FDA’s decision — and whether using HRT to treat menopause symptoms actually affects breast cancer risk.

  • by

  • January 28, 2026

  • 8 min